ChromoCure, Inc. Expands Capabilities for CS300 Series Chromosomal Scanner as Part of Genome Research Agreement

RENO, NV--(Marketwire - April 09, 2010) -

ChromoCure, Inc. (PINKSHEETS: KKUR) released today expanded specifications and capabilities for its next generation chromosomal scanner. The CS300 system now includes significant new features and capabilities. The new technology being incorporated into the CS300 is a direct result of the company’s recently announced relationship with Genome Research Group.

The base CS300 includes the following base specifications:

- Fully automated cell sample preparation cycling, automated multi-patient, multi-sample cell application to slide matrix array, On-Slide direct application of DNA-probes using robotic micro-application, and user-selectable chromosome probe types -- one probe or multiple simultaneous probes. Full integration of de-paraffinization and cellular disaggregation of tissue samples for non-cytology originated diagnostics.

The expanded CS300 feature set now includes:

• Aneuploidy scaling and cancer progression graphing and DNA-index curve fitting
• Ability to detect and store cancer progression and remission results over time
• Cancer remission and progression predictive algorithms using aneuploidy scaling
• Animal scanning capability using species specific DNA-probes for use in clinical trials of therapeutic models
• Time based daily progression and remission scanning and analysis incorporated into therapeutic testing and model
• Expanded user reporting and graphing capabilities for progression, remission, and clinical outcome projection analysis

The Company recently announced its Joint Venture and Technology Sharing Agreement with Genome Research Group. GRG’s advanced Therapeutic Modeling Protocols, together with ChromoCure’s landmark Chromosomal Scanning Technology, further strengthens the Company’s leadership in Cancer Detection, Therapy and Cure, and puts new impetus to its groundbreaking Project Boveri: Finding the Cure.

The Company’s proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently relied upon by pathologists, including genetic or protein biomarker detection.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company’s proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.